Amryt Pharma Future Growth
Future criteria checks 5/6
Amryt Pharma is forecast to grow earnings and revenue by 53.9% and 26.3% per annum respectively while EPS is expected to grow by 50.8% per annum.
Key information
53.9%
Earnings growth rate
50.8%
EPS growth rate
| Pharmaceuticals earnings growth | 23.6% |
| Revenue growth rate | 26.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Apr 2023 |
Recent future growth updates
Recent updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions
Dec 09Chiasma surges on merger agreement with Amryt
May 05Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept
Feb 04Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder
Dec 23Amryt Group's Lojuxta receives marketing approval in Brazil
Dec 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 595 | 153 | N/A | N/A | 1 |
| 12/31/2024 | 428 | 141 | N/A | N/A | 2 |
| 12/31/2023 | 325 | -3 | 59 | N/A | 4 |
| 12/31/2022 | 266 | -64 | 34 | N/A | 4 |
| 9/30/2022 | 244 | -1 | 107 | 108 | N/A |
| 6/30/2022 | 239 | 3 | -32 | -30 | N/A |
| 3/31/2022 | 233 | 3 | 4 | 5 | N/A |
| 12/31/2021 | 223 | 1 | 14 | 16 | N/A |
| 9/30/2021 | 210 | -88 | -89 | -86 | N/A |
| 6/30/2021 | 203 | -81 | 46 | 50 | N/A |
| 3/31/2021 | 186 | -92 | 21 | 23 | N/A |
| 12/31/2020 | 183 | -105 | 24 | 27 | N/A |
| 9/30/2020 | 180 | -87 | 5 | 6 | N/A |
| 6/30/2020 | 140 | -92 | -18 | -17 | N/A |
| 3/31/2020 | 98 | -87 | -26 | -26 | N/A |
| 12/31/2019 | 58 | -63 | -38 | -37 | N/A |
| 12/31/2018 | 17 | -30 | -16 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMYT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Earnings vs Market: AMYT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMYT is expected to become profitable in the next 3 years.
Revenue vs Market: AMYT's revenue (26.3% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: AMYT's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMYT's Return on Equity is forecast to be high in 3 years time